highlights of the need for more evidence, 2 , 3 the representation of older adults in NCI trials has not improved, and FDA registration studies still report limited evidence on older adults. 4 – 8 Thus, most of what we know about cancer therapeutics is
Search Results
Advocating for Older Adults With Cancer: Merging Medicine and Law
Arti Hurria and Laura A. Levit
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021
Featured Updates to the NCCN Guidelines
Steven M. Horwitz, Stephen Ansell, Weiyun Z. Ai, Jeffrey Barnes, Stefan K. Barta, Mark W. Clemens, Ahmet Dogan, Aaron M. Goodman, Gaurav Goyal, Joan Guitart, Ahmad Halwani, Bradley M. Haverkos, Richard T. Hoppe, Eric Jacobsen, Deepa Jagadeesh, Allison Jones, Youn H. Kim, Neha Mehta-Shah, Elise A. Olsen, Barbara Pro, Saurabh A. Rajguru, Sima Rozati, Jonathan Said, Aaron Shaver, Andrei Shustov, Lubomir Sokol, Pallawi Torka, Carlos Torres-Cabala, Ryan Wilcox, Basem M. William, Jasmine Zain, Mary A. Dwyer, and Hema Sundar
, Kura Oncology, Inc., Kyowa Hakko Kirin Co., Ltd., ADCT, C4 Therapeutics, Curio, Myeloid Therapeutics, Verastem, Seattle Genetics, Inc., and Takeda Pharmaceuticals North America, Inc.; and that he has received grant/research support from Celgene
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022
Featured Updates to the NCCN Guidelines
Elizabeth A. Griffiths, Vivek Roy, Laura Alwan, Kimo Bachiashvili, John Baird, Rita Cool, Shira Dinner, Mark Geyer, John Glaspy, Ivana Gojo, Ashley Hicks, Avyakta Kallam, Wajih Zaheer Kidwai, Dwight D. Kloth, Eric H. Kraut, Daniel Landsburg, Gary H. Lyman, Anjlee Mahajan, Ryan Miller, Victoria Nachar, Seema Patel, Shiven Patel, Lia E. Perez, Adam Poust, Fauzia Riaz, Rachel Rosovsky, Hope S. Rugo, Shayna Simon, Sumithira Vasu, Martha Wadleigh, Kelly Westbrook, Peter Westervelt, Ryan A. Berardi, and Lenora Pluchino
., Ltd., and Takeda Pharmaceuticals North America, Inc.; grant/research support from Astex Pharmaceuticals, Blueprint Medicines, Bristol-Myers Squibb Company, Celgene Corporation, Celldex Therapeutics, and Genentech, Inc.; consulting fee from Alexion
NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022
Featured Updates to the NCCN Guidelines
Margaret von Mehren, John M. Kane III, Richard F. Riedel, Jason K. Sicklick, Seth M. Pollack, Mark Agulnik, Marilyn M. Bui, Janai Carr-Ascher, Edwin Choy, Mary Connelly, Sarah Dry, Kristen N. Ganjoo, Ricardo J. Gonzalez, Ashley Holder, Jade Homsi, Vicki Keedy, Ciara M. Kelly, Edward Kim, David Liebner, Martin McCarter, Sean V. McGarry, Nathan W. Mesko, Christian Meyer, Alberto S. Pappo, Amanda M. Parkes, Ivy A. Petersen, Matthew Poppe, Scott Schuetze, Jacob Shabason, Matthew B. Spraker, Melissa Zimel, Mary Anne Bergman, Hema Sundar, and Lisa E. Hang
Pharmaceuticals, Inc.; and serving as an advisor for Boehringer Ingelheim GmbH, Deciphera Pharmaceuticals, Inc., and GlaxoSmithKline. Seth M. Pollack, MD, Panel Member, has disclosed serving as an advisor for Adaptimmune Therapeutics plc, Deciphera
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023
Featured Updates to the NCCN Guidelines
Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, Babis Andreadis, Nancy L. Bartlett, L. Elizabeth Budde, Paolo F. Caimi, Julie E. Chang, Beth Christian, Sven DeVos, Bhagirathbhai Dholaria, Luis E. Fayad, Thomas M. Habermann, Muhammad Saad Hamid, Francisco Hernandez-Ilizaliturri, Boyu Hu, Mark S. Kaminski, Yasmin Karimi, Christopher R. Kelsey, Rebecca King, Susan Krivacic, Ann S. LaCasce, Megan Lim, Marcus Messmer, Mayur Narkhede, Rachel Rabinovitch, Praveen Ramakrishnan, Erin Reid, Kenneth B. Roberts, Hayder Saeed, Stephen D. Smith, Jakub Svoboda, Lode J. Swinnen, Joseph Tuscano, Julie M. Vose, Mary A. Dwyer, and Hema Sundar
Products, LP,MEI Pharma Inc.,MorphoSys AG, Novartis Pharmaceuticals Corporation, and Roche Laboratories, Inc.; serving as a scientific advisor for Adaptive Biotechnologies, ADC Therapeutics, Arvinas, and Eli Lilly and Company; and receiving grant
Clinical Trials in the Age of Pandemics
Martin J. Edelman, Crystal S. Denlinger, Eric A. Ross, and Margaret von Mehren
locally advanced cancer. Even for diseases for which therapeutics have achieved high cure rates, there are trials evaluating strategies to minimize duration and toxicity of treatment. The effort required to formulate, activate, accrue, and analyze trials
Updates to the Management of Patients With Relapsed or Refractory Indolent Follicular and Marginal Zone Lymphomas
Presented by: Ann S. LaCasce and Ariela Noy
Therapeutics announced the voluntary withdraw of umbralisib (UKONIQ) from sale for the approved indications of adult patients with MZL who have received at least one prior anti-CD20–based regimen and for adult patients with FL who have received at least 3 prior
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019
William G. Wierda, John C. Byrd, Jeremy S. Abramson, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, Asher A. Chanan-Khan, Julio C. Chavez, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Shuo Ma, Sami Malek, Anthony Mato, Claudio Mosse, Vishala T. Neppalli, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Nina Wagner, Mary A. Dwyer, and Hema Sundar
/research support from AbbVie, Inc.; Acerta Pharma, LLC; Cyclacel Pharmaceuticals, Inc.; Gilead Sciences, Inc.; Intrexon Corporation; Juno Therapeutics, Inc.; Kite Pharma, Inc.; Oncternal Therapeutics; Precigen, Inc.; Xencor, Inc.; Pharmacyclics, Inc.; Roche
Systemic Management of Colorectal Cancer
Wells A. Messersmith
“You really can't treat colorectal cancer [CRC] today without molecular testing,” remarked Wells A. Messersmith, MD, Co-Director of the Developmental Therapeutics Program, University of Colorado Cancer Center, and Professor of Medicine, Director
Active Systemic Treatment of Pancreatic Cancer
Margaret Tempero
Biotech Resources, LLC, NeoHealth Inc., Novocure, Opsona Therapeutics, Portola Pharmaceuticals, Inc., and Threshold Pharmaceuticals Inc.; and grant/research support from Celgene Corporation and Halozyme Therapeutics, Inc.; and she has served as a
